Recall

Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

Recall from a federal regulator

Headline as published by U.S. Food and Drug Administration (MedWatch) on Oct 14, 2026; collected by the wire Oct 14, 2026, 12:15 PM ET.

Read at U.S. Food and Drug Administration (MedWatch)

FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terepht

From U.S. Food and Drug Administration (MedWatch)’s feed

Coverage

  1. U.S. Food and Drug Administration (MedWatch) Federal regulators

    Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method